ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Robert J. Motzer, Chung‐Han Lee, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka N. Vaishampayan, R Graham, S. Liu, Steve McCune, Montaser Shaheen, Hema Parmar, Yuning Shen, Sam H. Whiting, Nizar M. TannirAnnals 2019 · DOI

BibTeX
@article{motzer2019entrata,
  author = {Robert J. Motzer and Chung‐Han Lee and Hamid Emamekhoo and Marc Matrana and Ivor Percent and James J. Hsieh and Arif Hussain and Ulka N. Vaishampayan and R Graham and S. Liu and Steve McCune and Montaser Shaheen and Hema Parmar and Yuning Shen and Sam H. Whiting and Nizar M. Tannir},
  title = {{ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)}},
  journal = {Annals},
  year = {2019},
  doi = {10.1093/annonc/mdz394.048},
}

Loading related content...

Figure